{"analyses":[{"ciLowerLimit":"14.3","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"26.6","estimateComment":"Strata adjusted difference based on Cochran-Mantel-Haenszel (CMH) method of weighting.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"DIFFERENCE OF PCR","paramValue":"20.5"},{"ciLowerLimit":"3.40","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"12.97","estimateComment":"Strata adjusted odds ratio using Mantel-Haenszel method.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"6.64"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.8","upperLimit":"31.5","value":"25.3"},{"groupId":"OG001","lowerLimit":"2.4","upperLimit":"8.3","value":"4.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"232"}],"units":"Participants"}],"description":"Pathologic complete response (pCR) rate is defined as the percentage of randomized participants with absence of residual viable tumor in lung and lymph nodes as evaluated by blinded independent pathology review (BIPR).","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 360 mg Q3W + SOC platinum-based doublet chemotherapy Q3W x 4 cycles as neoadjuvant treatment followed by surgery; then post surgery nivolumab 480 mg Q4W adjuvant treatment for up to 13 cycles (approximately 1 year)","id":"OG000","title":"Nivolumab + SOC Chemotherapy"},{"description":"Placebo Q3W + SOC platinum-based doublet chemotherapy Q3W x 4 cycles as neoadjuvant treatment followed by surgery, then post-surgery placebo Q4W for up to 13 cycles (approximately 1 year).","id":"OG001","title":"Placebo + SOC Chemotherapy"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization up to approximately 44 months","title":"Pathologic Complete Response (pCR) Rate","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}